Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin

Gynecologic Oncology

Volumn 121, Issue 1, 2011, Pages 212-217

  Growdon, Whitfield B ^b,c   Roussel, Breton N ^a   Scialabba, Vanessa L ^a   Foster, Rosemary ^b,c   Dias Santagata, Dora ^b,c   Iafrate, A John ^b,c   Ellisen, Leif W ^a,c   Tambouret, Rosemary H ^b,c   Rueda, Bo R ^b,c   Borger, Darrell R ^a,c  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Carcinosarcoma; Genotyping; KRAS; Metaplastic carcinoma; Mutation; PIK3CA

Indexed keywords

K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53;

ADULT; AGE; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CARCINOMA; CARCINOSARCOMA; FEMALE; GENE; GENE MUTATION; GENOTYPE; GYNECOLOGIC CANCER; GYNECOLOGIC CARCINOSARCOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; OVARY CANCER; PIK3CA GENE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SARCOMA; SOMATIC MUTATION; TISSUE SPECIFICITY; TUMOR GENE; UTERINE TUBE DISEASE; UTERUS CANCER; VAGINA CANCER;

AGED; AGED, 80 AND OVER; BETA CATENIN; CARCINOSARCOMA; COHORT STUDIES; FEMALE; GENES, RAS; GENITAL NEOPLASMS, FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 79952815850     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.11.039     Document Type: Article

References (50)

1. Sit AS, Price FV, Kelley JL, Comerci JT, Kunschner AJ, Kanbour-Shakir A, et al. Chemotherapy for malignant mixed Mullerian tumors of the ovary. Gynecol Oncol 2000;79:196-200.
2. Inthasorn P, Carter J, Valmadre S, Beale P, Russell P, Dalrymple C. Analysis of clinicopathologic factors in malignant mixed Mullerian tumors of the uterine corpus. Int J Gynecol Cancer 2002;12:348-53. (Pubitemid 34839832)
3. Thigpen J Tate, Blessing JA, DeGeest K, Look KY, Homesley HD. Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study. Gynecol Oncol 2004;93:336-9. (Pubitemid 38507598)
4. Wright JD, Seshan VE, Shah M, Schiff PB, Burke WM, Cohen CJ, et al. The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma. Am J Obstet Gynecol 2008;199:536 e1-8.
5. Homesley HD, Filiaci V, Markman M, Bitterman P, Eaton L, Kilgore LC, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:526-31. (Pubitemid 350002959)
6. Gonzalez Bosquet J, Terstriep SA, Cliby WA, Brown-Jones M, Kaur JS, Podratz KC, et al. The impact of multi-modal therapy on survival for uterine carcinosarcomas. Gynecol Oncol 2010;116:419-23.
7. Wada H, Enomoto T, Fujita M, Yoshino K, Nakashima R, Kurachi H, et al. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res 1997;57:5379-85. (Pubitemid 27516377)
8. Abeln EC, Smit VT, Wessels JW, de Leeuw WJ, Cornelisse CJ, Fleuren GJ. Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed mullerian tumours. J Pathol 1997;183:424-31. (Pubitemid 27509249)
9. Fujii H, Yoshida M, Gong ZX, Matsumoto T, Hamano Y, Fukunaga M, et al. Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. Cancer Res 2000;60:114-20. (Pubitemid 30058740)
10. Taylor NP, Zighelboim I, Huettner PC, Powell MA, Gibb RK, Rader JS, et al. DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis. Mod Pathol 2006;19:1333-8. (Pubitemid 44423080)
11. Jin Z, Ogata S, Tamura G, Katayama Y, Fukase M, Yajima M, et al. Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis. Int J Gynecol Pathol 2003;22:368-73. (Pubitemid 37152987)
12. Kounelis S, Jones MW, Papadaki H, Bakker A, Swalsky P, Finkelstein SD. Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components. Hum Pathol 1998;29:82-7. (Pubitemid 28049550)
13. McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer 2002;12:687-90. (Pubitemid 35388035)
14. Silverberg SG, Major FJ, Blessing JA, Fetter B, Askin FB, Liao SY, et al. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 1990;9:1-19. (Pubitemid 20067452)
15. McCluggage WG. Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? J Clin Pathol 2002;55:321-5.
16. Bland AE, Stone R, Heuser C, Shu J, Jazaeri A, Shutter J, et al. A clinical and biological comparison between malignant mixed mullerian tumors and grade 3 endometrioid endometrial carcinomas. Int J Gynecol Cancer 2009;19:261-5.
17. George E, Lillemoe TJ, Twiggs LB, Perrone T. Malignant mixed mullerian tumor versus high-grade endometrial carcinoma and aggressive variants of endometrial carcinoma: a comparative analysis of survival. Int J Gynecol Pathol 1995;14: 39-44.
18. Amant F, Cadron I, Fuso L, Berteloot P, de Jonge E, Jacomen G, et al. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecol Oncol 2005;98:274-80. (Pubitemid 41019116)
19. Garg G, Shah JP, Kumar S, Bryant CS, Munkarah A, Morris RT. Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes. Int J Gynecol Cancer 2010;20:888-94.
20. Schipf A, Mayr D, Kirchner T, Diebold J. Molecular genetic aberrations of ovarian and uterine carcinosarcomas-a CGH and FISH study. Virchows Arch 2008;452: 259-68.
21. Amant F, Vloeberghs V, Woestenborghs H, Debiec-Rychter M, Verbist L, Moerman P, et al. ERBB-2 gene overexpression and amplification in uterine sarcomas. Gynecol Oncol 2004;95:583-7. (Pubitemid 39592525)
22. Sawada M, Tsuda H, Kimura M, Okamoto S, Kita T, Kasamatsu T, et al. Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma. Cancer Sci 2003;94:986-91.
23. Livasy CA, Reading FC, Moore DT, Boggess JF, Lininger RA. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecol Oncol 2006;100:101-6. (Pubitemid 41815057)
24. Murray S, Linardou H, Mountzios G, Manoloukos M, Markaki S, Eleutherakis- Papaiakovou E, et al. Low frequency of somatic mutations in uterine sarcomas: a molecular analysis and review of the literature. Mutat Res 2010;686:68-73.
25. Raspollini MR, Susini T, Amunni G, Paglierani M, Castiglione F, Garbini F, et al. Expression and amplification of HER-2/neu oncogene in uterine carcinosarcomas: a marker for potential molecularly targeted treatment? Int J Gynecol Cancer 2006;16:416-22.
26. Raspollini MR, Susini T, Amunni G, Paglierani M, Taddei A, Marchionni M, et al. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies? Gynecol Oncol 2005;96: 159-67.
27. Cimbaluk D, Rotmensch J, Scudiere J, Gown A, Bitterman P. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets. Gynecol Oncol 2007;105:138-44. (Pubitemid 46441450)
28. Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med 2010;2:146-58.
29. Watanabe M, Shimizu K, Kato H, Imai H, Nakano H, Sugawa M, et al. Carcinosarcoma of the uterus: immunohistochemical and genetic analysis of clonality of one case. Gynecol Oncol 2001;82:563-7. (Pubitemid 32826460)
30. Seki A, Kodama J, Miyagi Y, Kamimura S, Yoshinouchi M, Kudo T. Amplification of the mdm-2 gene and p53 abnormalities in uterine sarcomas. Int J Cancer 1997;73: 33-7. (Pubitemid 27445987)
31. Cho KR, Shih Ie M. Ovarian cancer. Annu Rev Pathol 2009;4:287-313.
32. Di Cristofano A, Ellenson LH. Endometrial carcinoma. Annu Rev Pathol 2007;2: 57-85. (Pubitemid 46448060)
33. Oda K, Stokoe D, Taketani Y, McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 2005;65: 10669-73. (Pubitemid 41713332)
34. Wolfson AH, BradyMF, Rocereto T,Mannel RS, Lee YC, Futoran RJ, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol 2007;107:177-85. (Pubitemid 47575740)
35. Podczaski ES, Woomert CA, Stevens Jr CW, Manetta A, Larson JE, Zaino RJ, et al. Management of malignant, mixed mesodermal tumors of the uterus. Gynecol Oncol 1989;32:240-4. (Pubitemid 19041970)
36. Hannigan EV, Freedman RS, Rutledge FN. Adjuvant chemotherapy in early uterine sarcoma. Gynecol Oncol 1983;15:56-64. (Pubitemid 13194684)
37. Sutton G, Kauderer J, Carson LF, Lentz SS, Whitney CW, Gallion H. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2005;96:630-4. (Pubitemid 40255480)
38. Slayton RE, Blessing JA, DiSaia PJ, Christopherson WA. Phase II trial of etoposide in the management of advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study. Cancer Treat Rep 1987;71:661-2. (Pubitemid 17090275)
39. Omura GA, Major FJ, Blessing JA, Sedlacek TV, Thigpen JT, Creasman WT, et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 1983;52:626-32. (Pubitemid 13025913)
40. Thigpen JT, Blessing JA, Orr Jr JW, DiSaia PJ. Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study. Cancer Treat Rep 1986;70:271-4. (Pubitemid 16166174)
41. Sutton GP, Blessing JA, Rosenshein N, Photopulos G, DiSaia PJ. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study). Am J Obstet Gynecol 1989;161:309-12. (Pubitemid 19212192)
42. Miller DS, Blessing JA, Schilder J, Munkarah A, Lee YC. Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2005;98:217-21. (Pubitemid 41019108)
43. Nimeiri HS, Oza AM, Morgan RJ, Huo D, Elit L, Knost JA, et al. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 2010;117:37-40.
44. Huh WK, Sill MW, Darcy KM, Elias KM, Hoffman JS, Boggess JF, et al. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c- Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus. Gynecol Oncol 2010;117: 248-54.
45. Nakayama M, Mitsuhashi T, Shimizu Y, Ban S, Ogawa F, Ishihara O, et al. Immunohistochemical evaluation of KIT expression in sarcomas of the gynecologic region. Int J Gynecol Pathol 2006;25:70-6. (Pubitemid 44638339)
46. Raspollini MR, Amunni G, Villanucci A, Pinzani P, Simi L, Paglierani M, et al. c-Kit expression in patients with uterine leiomyosarcomas: a potential alternative therapeutic treatment. Clin Cancer Res 2004;10:3500-3. (Pubitemid 38685458)
47. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci USA 2007;104: 19936-41.
48. Weinstein IB. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002;297:63-4.
49. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007;446:153-8. (Pubitemid 46398669)
50. Sharma SV, Fischbach MA, Haber DA, Settleman J. "Oncogenic shock": explaining oncogene addiction through differential signal attenuation. Clin Cancer Res 2006;12:4392s-5s.